The Weight Loss Peptide Landscape
The year 2021 changed the conversation about obesity medicine forever. When the STEP-1 trial published semaglutide’s Phase III results — 14.9% mean body weight reduction at 68 weeks — it was the largest efficacy signal seen in a pharmacological weight loss trial. The subsequent approval of tirzepatide with 22.5% weight loss in the SURMOUNT-1 trial set a new benchmark.
The GLP-1 class didn’t just produce better numbers than existing drugs. It produced numbers that had previously been achievable only through bariatric surgery.
This guide separates that well-established evidence from the noise around other compounds marketed for weight loss.
Tier 1: Strong RCT Evidence (FDA Approved)
Semaglutide (Ozempic/Wegovy)
Mechanism: GLP-1 receptor agonist. Slows gastric emptying, reduces appetite via hypothalamic GLP-1R activation, stimulates glucose-dependent insulin secretion.
Key Evidence:
- STEP-1 (2021): 1,961 adults, 68 weeks. 14.9% mean weight loss vs. 2.4% placebo. 86.4% achieved ≥5% weight loss.
- STEP-4 (2021): Weight regain upon discontinuation — underscoring that effects require continued treatment.
- SELECT (2023): 17,604 adults with obesity and CVD (but no diabetes). 20% reduction in MACE. Weight loss was secondary — the primary CV benefit was separable.
Real-world considerations: Supply chain disruptions, cost (~$1,300/month without insurance), and the need for indefinite continuation to maintain results are practical factors for patients.
Evidence Grade: 🟢 EL1 — Multiple large RCTs, FDA approved, independent replication
Tirzepatide (Mounjaro/Zepbound)
Mechanism: Dual GIP/GLP-1 receptor agonist. Activates both incretin receptors simultaneously for synergistic metabolic effect.
Key Evidence:
- SURMOUNT-1 (2022): 2,539 adults. 15 mg dose: 22.5% mean weight loss. 63% achieved ≥20% weight loss.
- SURMOUNT-4 (2023): Demonstrated that stopping tirzepatide leads to weight regain; continuation superior to switch to placebo.
- SURPASS-2 (2021): Head-to-head vs. semaglutide 1 mg — tirzepatide superior for both HbA1c and weight. (Note: 1 mg is the diabetes dose, not the 2.4 mg weight dose.)
Evidence Grade: 🟢 EL1 — FDA approved (Zepbound 2023)
Liraglutide (Saxenda)
Mechanism: GLP-1 receptor agonist, once-daily injection. Largely superseded by semaglutide in clinical practice due to less frequent dosing and greater efficacy.
Key Evidence:
- SCALE (2015): 8.4% mean weight loss vs. 2.8% placebo at 56 weeks.
Evidence Grade: 🟢 EL1 — FDA approved (Saxenda 2014)
Tier 2: Emerging FDA-Approved Agents
Retatrutide (Phase III)
Triple receptor agonist (GIP/GLP-1/Glucagon) in late-stage trials. Phase II data showed ~24% weight loss at 48 weeks — potentially exceeding tirzepatide. FDA approval expected 2025–2026.
Evidence Grade: 🟡 EL2 — Phase II completed; Phase III ongoing
Tier 3: Research-Only Compounds (No FDA Approval)
CJC-1295 + Ipamorelin (GH Secretagogue Stack)
Rationale: Growth hormone promotes lipolysis (fat breakdown) and has anabolic effects on lean mass. GHRH + GHRP stacks aim to restore youthful GH pulsatility.
What the evidence shows: The GH axis peptides have legitimate Phase I human data showing they increase GH and IGF-1. However, studies specifically examining body composition changes in humans are limited. The fat-loss effects observed in aging populations with low baseline IGF-1 do not necessarily translate to people with normal GH function.
Key limitation: Most body composition claims come from GH replacement therapy (exogenous GH) research, not from GH secretagogue-specific trials.
Evidence Grade: 🟠 EL3 — Mechanism validated; body composition effects in humans limited data
AOD-9604
What it is: A modified fragment of growth hormone (hGH 176-191) designed to have GH’s fat-burning effects without its growth-promoting or insulin-desensitizing effects.
Rationale: In rodent studies, AOD-9604 stimulated lipolysis without affecting blood glucose or IGF-1 — an appealing separation of effects.
What the evidence shows: Phase IIb trials in humans showed no significant weight loss vs. placebo. Metaboliq (the Australian company developing it) discontinued clinical development after disappointing human results. The compound is still widely marketed in research communities despite failed human trials.
Evidence Grade: 🔴 EL4 — Failed Phase IIb trials; animal-based claims not replicated in humans
Tesamorelin (Egrifta)
FDA Approved for: HIV-associated lipodystrophy (abnormal fat accumulation in the abdomen as a side effect of HIV therapy).
Off-label weight loss: Tesamorelin is a GHRH analog with some evidence for visceral fat reduction specifically. A 52-week trial showed 11% reduction in visceral fat in HIV patients. Studies in healthy adults with obesity are limited.
Evidence Grade: 🟡 EL2 — FDA approved for specific indication; limited data in general obesity
Semaglutide Compounded (Grey Market)
Post-2022, many compounding pharmacies produced “compounded semaglutide” — some of which included tirzepatide acetate (a salt form rather than the free base). The FDA declared the GLP-1 shortage resolved in 2024, after which compounding semaglutide became illegal under 503A. Quality and authenticity of grey-market GLP-1s vary enormously.
Recommendation: Use FDA-approved branded products or verified 503A pharmacy preparations when legal.
What Actually Drives Weight Loss Results
Regardless of which peptide is used, the mechanisms that produce sustainable results are:
- Caloric deficit — GLP-1 agonists work primarily by helping maintain a caloric deficit through appetite suppression and slower gastric emptying
- Lean mass preservation — ideally paired with resistance training and adequate protein (1.6+ g/kg body weight)
- Behavioral change — the appetite reduction window should ideally be used to establish sustainable eating patterns
- Continued treatment — STEP-4 and SURMOUNT-4 demonstrate clearly that discontinuation leads to weight regain in most patients
Practical Considerations
Cost and access: Wegovy and Zepbound are expensive (~$1,200–1,500/month list price). Insurance coverage is expanding but inconsistent. Manufacturer savings cards reduce cost for some commercially insured patients.
Who is not a candidate:
- Personal/family history of medullary thyroid carcinoma or MEN2 (GLP-1 class contraindication)
- Active pancreatitis
- Severe GI motility disorders
- Pregnancy or breastfeeding
Monitoring during GLP-1 therapy:
- HbA1c and fasting glucose (baseline and follow-up)
- Kidney function (GFR)
- Thyroid function (if clinically indicated)
- Body composition (DEXA) if available — to track lean vs. fat mass changes
Summary Table
| Compound | Evidence | FDA Status | Avg Weight Loss | Notes |
|---|---|---|---|---|
| Semaglutide 2.4 mg | EL1 | Approved (Wegovy) | ~15% | Gold standard |
| Tirzepatide 15 mg | EL1 | Approved (Zepbound) | ~22% | Best current efficacy |
| Liraglutide 3 mg | EL1 | Approved (Saxenda) | ~8% | Once-daily; largely superseded |
| Retatrutide | EL2 | Phase III | ~24% | Not yet approved |
| CJC-1295 + Ipamorelin | EL3 | Not approved | Unknown in RCT | Indirect mechanism |
| AOD-9604 | EL4 | Not approved | Failed in Phase IIb | Do not use for weight loss |
Conclusion
The evidence landscape for peptide weight loss is bifurcated: the GLP-1 class has extraordinary Phase III data and FDA approval; most other research-only compounds have either weak evidence or, in the case of AOD-9604, failed human trials. Making treatment decisions based primarily on the strength of animal data or community anecdotes — rather than peer-reviewed human clinical evidence — is a significant risk management failure.
For anyone considering peptide therapy for weight management, the conversation should start with the approved GLP-1 options, and any departure from that should be accompanied by rigorous evidence review with a knowledgeable provider.